Inhibikase Therapeutics, Inc 10-K/A, filed Oct 16, 2023
Inhibikase Therapeutics, Inc. (IKT)
About this 10-K/A
Inhibikase Therapeutics, Inc filed this 10-K/A on October 16, 2023, covering the fiscal year ended December 31, 2022.
ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO |
(State or other jurisdiction of incorporation or organization) |
(I.R.S. Employer Identification No.) | |
(Address of principal executive offices) |
(Zip Code) | |
Title of each class |
Trading Symbol(s) |
Name of each exchange on which registered | ||
| Large accelerated filer | ☐ | Accelerated filer | ☐ | |||
Non-accelerated filer |
☒ | Smaller reporting company | ||||
| Emerging growth company | ||||||
| Auditors Name : |
Auditors Location: |
Auditors Firm ID : PCAOB |
Where Located | ||||||||||||
Exhibit Number |
Description* |
Form |
File Number |
Exhibit Number |
Filing Date |
Filed Herewith | ||||||
| 23.1 | Consent of Independent Registered Public Accounting Firm. | x | ||||||||||
| 31.1 | Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 | x | ||||||||||
| 31.2 | Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 | x | ||||||||||
| 101.INS | Inline XBRL Instance Document – the instance document does not appear in the Interactive Data File because XBRL tags are embedded within the Inline XBRL document. | x | ||||||||||
| 101.SCH | Inline XBRL Taxonomy Extension Schema Document | x | ||||||||||
| 101.CAL | Inline XBRL Taxonomy Extension Calculation Linkbase Document | x | ||||||||||
| 101.DEF | Inline XBRL Taxonomy Extension Definition Linkbase Document | x | ||||||||||
| 101.LAB | Inline XBRL Taxonomy Extension Label Linkbase Document | x | ||||||||||
| 101.PRE | Inline XBRL Taxonomy Extension Presentation Linkbase Document | x | ||||||||||
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) | x | ||||||||||
| Inhibikase Therapeutics, Inc. | ||||||
| Date: October 16, 2023 | By: | /s/ MILTON H. WERNER, Ph.D. | ||||
| Milton H. Werner, Ph.D. | ||||||
President and Chief Executive Officer (Principal Executive Officer) | ||||||
EXHIBIT 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We consent to the incorporation by reference in the following Registration Statements:
| • | Form S-3 (File No. 333-262551) of Inhibikase Therapeutics, Inc., and |
| • | Form S-8 (File No. 333-259555) pertaining to the Inhibikase Therapeutics, Inc. 2020 Equity Incentive Plan of Inhibikase Therapeutics, Inc.; |
of our report dated March 31, 2023, with respect to the consolidated financial statements of Inhibikase Therapeutics, Inc. and Subsidiary included in this Annual Report (Form 10-K) of Inhibikase Therapeutics, Inc. and Subsidiary for the years ended December 31, 2022 and December 31, 2021.
| /s/ CohnReznick LLP |
| Holmdel, New Jersey |
| March 31, 2023 |
EXHIBIT 31.1
CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER
PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
I, Milton H. Werner, certify that:
1. I have reviewed this Amendment No. 1 to the Annual Report on Form 10-K/A of Inhibikase Therapeutics, Inc.; and
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report.
| Date: October 16, 2023 | ||||||
| /s/ Milton H. Werner | ||||||
| Milton H. Werner, Ph.D. | ||||||
| President and Chief Executive Officer (Principal Executive Officer) | ||||||
EXHIBIT 31.2
CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER
PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
I, Joseph Frattaroli, certify that:
1. I have reviewed this Amendment No. 1 to the Annual Report on Form 10-K/A of Inhibikase Therapeutics, Inc.; and
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report.
| Date: October 16, 2023 | ||||||
| /s/ Joseph Frattaroli | ||||||
| Joseph Frattaroli | ||||||
| Chief Financial Officer (Principal Financial Officer and Principal Accounting Officer) | ||||||